vs
Side-by-side financial comparison of Primis Financial Corp. (FRST) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $45.6M, roughly 1.3× Primis Financial Corp.). Primis Financial Corp. runs the higher net margin — 16.0% vs -83.0%, a 99.0% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 13.0%).
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
FRST vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $45.6M | $57.3M |
| Net Profit | $7.3M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | — | -82.2% |
| Net Margin | 16.0% | -83.0% |
| Revenue YoY | — | 36.9% |
| Net Profit YoY | 200.0% | -9.6% |
| EPS (diluted) | $0.30 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.6M | — | ||
| Q4 25 | $80.9M | $57.3M | ||
| Q3 25 | $41.0M | $51.3M | ||
| Q2 25 | $43.2M | $48.5M | ||
| Q1 25 | $58.7M | $32.7M | ||
| Q4 24 | $38.8M | $41.8M | ||
| Q3 24 | $37.3M | $33.3M | ||
| Q2 24 | $35.7M | $29.1M |
| Q1 26 | $7.3M | — | ||
| Q4 25 | $29.5M | $-47.5M | ||
| Q3 25 | $6.8M | $-52.9M | ||
| Q2 25 | $2.4M | $-46.6M | ||
| Q1 25 | $22.6M | $-49.5M | ||
| Q4 24 | $-26.2M | $-43.3M | ||
| Q3 24 | $1.2M | $-43.6M | ||
| Q2 24 | $3.4M | $-32.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | -82.2% | ||
| Q3 25 | 21.3% | -102.6% | ||
| Q2 25 | 6.9% | -93.4% | ||
| Q1 25 | 41.9% | -143.7% | ||
| Q4 24 | -123.0% | -98.6% | ||
| Q3 24 | -3.1% | -132.0% | ||
| Q2 24 | 7.8% | -139.2% |
| Q1 26 | 16.0% | — | ||
| Q4 25 | 36.5% | -83.0% | ||
| Q3 25 | 16.7% | -103.1% | ||
| Q2 25 | 5.6% | -96.1% | ||
| Q1 25 | 38.6% | -151.4% | ||
| Q4 24 | -100.3% | -103.6% | ||
| Q3 24 | 3.3% | -131.2% | ||
| Q2 24 | 9.6% | -110.9% |
| Q1 26 | $0.30 | — | ||
| Q4 25 | $1.19 | $-0.73 | ||
| Q3 25 | $0.28 | $-0.82 | ||
| Q2 25 | $0.10 | $-0.75 | ||
| Q1 25 | $0.92 | $-0.81 | ||
| Q4 24 | $-0.95 | $-0.71 | ||
| Q3 24 | $0.05 | $-0.73 | ||
| Q2 24 | $0.14 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.9M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $427.2M | $139.1M |
| Total Assets | $4.3B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $159.9M | — | ||
| Q4 25 | $143.6M | $388.9M | ||
| Q3 25 | $63.9M | $416.1M | ||
| Q2 25 | $94.1M | $291.0M | ||
| Q1 25 | $57.0M | $314.5M | ||
| Q4 24 | $64.5M | $320.6M | ||
| Q3 24 | $77.3M | $298.4M | ||
| Q2 24 | $66.6M | $319.1M |
| Q1 26 | $427.2M | — | ||
| Q4 25 | $422.9M | $139.1M | ||
| Q3 25 | $382.2M | $148.8M | ||
| Q2 25 | $376.4M | $-11.9M | ||
| Q1 25 | $375.6M | $18.9M | ||
| Q4 24 | $351.8M | $21.7M | ||
| Q3 24 | $381.0M | $11.2M | ||
| Q2 24 | $376.0M | $39.3M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.0B | $480.2M | ||
| Q3 25 | $4.0B | $506.9M | ||
| Q2 25 | $3.9B | $372.7M | ||
| Q1 25 | $3.7B | $386.7M | ||
| Q4 24 | $3.7B | $392.3M | ||
| Q3 24 | $4.0B | $363.6M | ||
| Q2 24 | $4.0B | $381.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.8M | $-25.4M | ||
| Q3 25 | $-11.4M | $-26.6M | ||
| Q2 25 | $-41.0M | $-23.3M | ||
| Q1 25 | $34.4M | $-40.4M | ||
| Q4 24 | $19.5M | $-18.8M | ||
| Q3 24 | $6.1M | $-25.2M | ||
| Q2 24 | $52.3M | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $18.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 11.2% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 47.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.36× | — | ||
| Q3 25 | -1.67× | — | ||
| Q2 25 | -16.82× | — | ||
| Q1 25 | 1.52× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.93× | — | ||
| Q2 24 | 15.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
RYTM
Segment breakdown not available.
